Molecular biomarkers for weight control in obese individuals subjected to a multi-phase dietary intervention

Jennifer Bolton¹², Emilie Montastier¹²³, Jérôme Carayol⁴, Sophie Bonnel¹², Lucile Mir¹², Marie-Adeline Marques¹², Jason Iacovoni¹², Nathalie Villa-Vialaneix⁵, Armand Valsesia⁴, Dominique Langin¹²³, and Nathalie Viguerie¹²

¹ Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1048, Obesity Research Laboratory, Institute of Metabolic and Cardiovascular Diseases (I2MC), Toulouse, France;
² University of Toulouse, UMR1048, Paul Sabatier University, Toulouse, France;
³ Toulouse University Hospitals, Departments of Endocrinology, Metabolism and Nutrition, Toulouse, France;
⁴ Nestlé Institute of Health Sciences SA, EPFL Innovation Park, Bâtiment H, 1015 Lausanne, Switzerland;
⁵ Unité de Mathématiques et Informatique Appliquées de Toulouse (MIAT), Université de Toulouse, INRA, Castanet Tolosan, France

Abbreviated Title: Biomarkers of weight control

Key terms: gene expression; weight loss; calorie restriction; adipose tissue

Word count: 3579 (excluding references)

Number of figures and tables: 7

Corresponding author and person to whom reprint requests should be addressed:

Nathalie Viguerie
INSERM, UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC)
1 avenue Jean Poulhès
31432 Toulouse, France
Phone: +33561325631
Fax: +33561325600
email: nathalie.viguerie@inserm.fr

Grants
This work was supported by the Innovative Medicines Initiative Joint Undertaking (grant agreement n° 115372), Inserm, Paul Sabatier University and the Commission of the European Communities (FP6-513946 DiOGenes).
Disclosure Statement:

DL is a member of Institut Universitaire de France, JC and AV are employed by Nestlé, the other authors have nothing to disclose.

Clinical Trial Identifier:

NCT00390637
ABSTRACT

Context. While calorie restriction has proven beneficial for weight loss, long-term weight control is variable between individuals.

Objective. We aimed to identify biomarkers of weight control during a dietary intervention (DI), which included 8-weeks of calorie-restriction and 6-months of follow-up.

Design. Adipose tissue (AT) transcriptomes were compared between 21 obese individuals that had either good (maintained weight loss) or poor (regained weight) weight control during the DI. Selected genes were validated on 310 individuals from the same study using RT-qPCR, and protein levels of potential circulating biomarkers were measured by ELISA.

Results. We evaluated 4 genes that had altered expression during the DI, encode secreted proteins, and have not previously been implicated in weight control (EGFL6, FSTL3, CRYAB, IGFBP3); as well as 2 genes for which baseline expression was different between those with good and poor weight control (ASPN, USP53). Changes in plasma concentration of EGFL6, FSTL3, and CRYAB mirrored AT mRNA expression, all decreased during DI in individuals with good weight control. ASPN and USP53 had higher baseline expression in individuals that went on to have good weight control, and eQTL analysis found polymorphisms associated with expression levels of USP53 in AT. A regulatory network was identified in which TGFβ1 was responsible for down-regulation of certain genes during DI in good-controllers. Interestingly, ASPN is a TGFβ1 inhibitor.

Conclusions. This study found circulating biomarkers associated with weight control, which could serve to adjust weight management strategies, and genes that may be prognostic for successful weight control.
INTRODUCTION

Although obesity may appear to be a simple issue of increased body fat due to excess energy intake, effective guidance for weight control is lacking. Caloric restriction is generally first prescribed to lose weight, however maintenance of weight loss often remains an obstacle. While the extent to which a hypocaloric diet induces weight loss is heterogeneous, subsequent weight control shows even greater inter-individual variation. So far most attempts to predict weight loss during, or weight control after, caloric restriction have failed to provide useful predictive biomarkers (1).

Adipose tissue (AT) plays a pivotal role in obesity-related complications. In addition to storing and releasing excess energy loads, AT also secretes numerous bioactive factors, thus making it a potential source of biomarkers. Nutritional genomics can be used to determine how dietary interventions impact AT, and to identify genes that may cause or contribute to the development of obesity-related disease (2). Gene expression profiling studies in humans to identify transcriptional responses to diet and their molecular targets have shown that weight changes are a major contributor to altered AT gene expression (3-8).

In the present study, we used subcutaneous AT from obese individuals that followed a 8-month dietary intervention (DI), consisting of a 8-week calorie-restriction (CR) diet followed by a 6-month ad libitum follow-up. Discovery analyses used transcriptomics to identify genes that were differentially expressed between individuals that successfully maintained weight loss (good-controllers), and those that returned to their baseline weight during follow-up (poor-controllers). Validation analyses using RT-qPCR on a larger cohort confirmed identification of genes that show altered expression in response to weight changes during DI, as well as genes that have different expression levels at baseline, representing markers that are potentially indicative of an individual's ability to successfully maintain weight loss. Finally, for validated genes that encode secreted proteins, plasma protein levels were measured.

MATERIALS & METHODS

Subjects and clinical evaluation

These analyses used samples obtained from the DiOGenes Study (9), all participants signed an informed consent document after verbal and written instructions. As shown in Figure 1a, overweight individuals followed a low-calorie (800-1000 kcal/day) diet for 8 weeks; those that lost at least 8% of their baseline weight were randomized to one of four ad libitum follow-up diets or a control diet for 6 months (71% completed). Transcriptome analyses used individuals from the extremes of percentage weight change during DI (exclusion criteria are detailed in Supplementary Figure 1) that were group-matched for baseline age, weight, BMI, waist circumference, blood pressure, and insulin resistance measured by HOMA-IR (homeostatic model assessment index). This resulted in selection of 22 individuals: 11 good-controllers (either maintained weight loss or continued to lose during follow-up) and 11 poor-controllers (regained during follow-up, returning to their baseline weight).
Adipose tissue fractionation and ex vivo cell culture

Abdominal subcutaneous AT was obtained from 7 women (BMI 25.3±4.5 kg/m², age 27–50 years) undergoing plastic surgery. The study was approved by the University Hospital of Toulouse ethical committee, and conforms to the Declaration of Helsinki. From each AT sample, 1 gram was flash frozen and stored at -80°C, and 10 grams were digested using collagenase (10), adipocytes were separated from the SVF by washing and centrifugation. For use in gene expression analyses, adipocytes and SVF cells were homogenized in lysis buffer (miRNeasy kit, Qiagen) and stored at −80°C until RNA extraction. For use in secretion analyses, isolated packed adipocytes and SVF cells were maintained ex vivo at 37°C in endothelial culture basal medium with 0.1% fatty acid free bovine serum albumin at 2ml (500,000) adipocytes in 10ml medium or 300,000 SVF cells per 1ml medium, respectively. These conditioned media were collected after 24 hours, centrifuged, and stored at -80°C.

Enzyme-linked immunosorbent assays (ELISA)

Protein levels of EGFL6 (csb-el007475hu, Cusabio, Clinisciences, Nanterre, France), FSTL3 (CEK1166, Cohesion Biosciences, Clinisciences), CRYAB (csb-el006008hu, Cusabio, Clinisciences) and IGFBP3 (CEK1195, Cohesion Biosciences, Clinisciences) were measured in duplicate, following manufacturer’s instructions.

Gene expression studies

Transcriptome microarray assays

Total RNA was extracted from AT (11) and transcriptomes measured using Agilent Whole Human Genome Microarray 4x44K v2 according to the manufacturer’s recommendations (Agilent Technologies, design ID 026652) (6). Arrays were scanned using an InnoScan® 710 scanner (Innopsys, Carbonne, France), and images were quantified using MAPIX® v6.5.0 software (Innopsys). Microarray processing included background subtraction, loess intra-array normalization, and Gquantile inter-array normalization in limma (12).

RT-qPCR assays

cDNA was prepared from 500 ng of total RNA and processed using the Biomark™ HD system with 96.96 Dynamic Array IFC (BioMark) and TaqMan assays (Applied Biosystems) as described in (11). Raw data from the default global threshold setting (BioMark Real-time PCR Analysis V4.1.1, Fluidigm) were checked using the graphical representation of plate layout. Duplicate raw Ct values for the same gene were averaged, then relative gene expression was calculated as $2^{-\Delta\Delta Ct}$.

Statistical analyses

Clinical characteristics
All analyses used R version 3.2.2. Differences between groups used nonparametric Mann-Whitney U test. Robust mixed ANOVA with bootstrapping (13) applying multiple trimmed group means (default level of 20%) was used to compare within subject changes between groups, reporting the interaction effect.

**Adipose tissue transcriptome: differential expression**

Principal component analysis (PCA) of transcriptome data identified one individual as an outlier and as such was excluded, analyses included 11 good-controllers and 10 poor-controllers. Differential expression (DE) consisted of 3 separate analyses, comparing log₂ transformed measures between groups at: i) baseline, ii) end of the DI, and iii) intra-individual log₂ fold-changes during DI. Analyses used limma package (13) and all 35,274 spots, because limma relies on the spread of variances pre-filtering is not recommended. Duplicate probes were removed after modeling, keeping that with the smallest p-value (27,385 unique probes), q-values were calculated using the qvalue package (14) on gene-level data (18,568 Entrez Genes). Comparisons of results always represent the same probe.

**RT-qPCR validation**

RT-qPCR expression was measured for 310 individuals from the DiOGenes study. We applied linear regression models using age, sex, and change in BMI during DI as predictors, and either: i) log₂ transformed baseline expression, or ii) intra-individual log₂ fold-changes during DI, as dependent. For the latter, additional models added baseline BMI or an interaction with baseline BMI. PCA of RT-qPCR expression at end of DI showed that diet had no effect on global gene expression; addition of diet as a random effect to the above models did not alter results. Addition of centre as a random effect did not affect results when using intra-individual changes in expression, nor our top result when using baseline expression.

**eQTL analysis**

Genome-wide associations were performed using the Illumina 660 chip imputed with European 1000 Genomes (GRCh37) using Minimac3 (15), and log₂ transformed baseline mRNA expression measured by RT-qPCR in 346 individuals. QTL associations between single nucleotide polymorphisms (SNPs) and gene expression used linear mixed models (LMM). Transformed gene expression residuals from regression on age, sex, BMI and center were used as dependent, and individual SNPs as independent variables. GCTA software (16) was used for LMM computation with the 'loco' option to avoid deflation of the test statistics. The Genotype-Tissue Expression (GTEx) Portal (version 4.1, build 201), a database of human genome expression and regulation (17), was used to confirm results, reporting single-tissue eQTL p-values. LocusZoom (18) was used to display regional information of SNPs identified by eQTL analyses. eQTL were considered cis if lead SNPs were within 1Mb of the gene, and p<5E-08 was considered genome-wide significant.
Ingenuity Pathway Analysis (IPA, Qiagen, USA) was used to identify pathways and/or networks, using transcriptome expression ratios obtained from: i) DE results at end of DI for 86 genes that diverged (q<0.20 and absolute log$_2$ expression ratios >0.6), or ii) baseline DE results for 209 genes that classified poor- and good-responders (p<0.05) (Figure 1b). The 18,568 genes were used as reference dataset (direct and indirect relationships were permitted), and genes reported as located in “Extracellular Space” were considered to encode secreted factors.

RESULTS

Clinical characteristics of good- and poor-controllers

There was no difference in baseline BMI between good- and poor-controllers (p=0.504), nor were there any differences in clinical measures at baseline, although fasting fructosamine was marginally higher in good-controllers (p=0.078, Supplementary Table 1). Good-controllers lost more weight during CR than poor-controllers (13% vs. 9%, p<0.001). As expected, at the end of the DI good-controllers showed improved health status, with significant differences in changes of fat mass, waist circumference, SBP, LDL-cholesterol, and C-reactive protein between groups (Table 1).

Altered gene expression in response to the dietary intervention

Discovery analysis using microarrays

We considered genes to have diverged expression if they were differentially expressed at the end of DI, and had differences in log$_2$ fold-changes between poor- and good-controllers during DI. There were 202 diverged genes with q<0.20, of these 27 had q<0.05: 22 were down-regulated and 5 were up-regulated in good-controllers, but remained unchanged in poor-controllers (Table 2 & Figure 2a). Of these 27 genes, 6 encoded secreted proteins (LOXL2, IGFBP3, HTRA1, LEP, EGFL6, SPARC).

Pathway analysis

IPA analysis using 86 genes with diverged expression (q<0.20 & expression ratio at end of DI>0.6) found a regulatory network centered on TGFB1, due to the observed higher expression levels of LOX, LOXL2, LAMB3, SPARC, CCND1, and INHBB in poor-controllers at the end of the DI (Supplementary Figure 2). These genes were up-regulated in poor-controllers and down-regulated in good-controllers during DI (Supplementary Table 3).

Validation analyses using RT-qPCR

We validated 22 out of 24 genes selected from the 202 diverged genes (q<0.20), using RT-qPCR. These 24 genes (9 with q<0.05, 15 with 0.05<q<0.20) were selected based on either the largest absolute DE, or potential to encode secreted factors. All 9 genes with q<0.05 in DE analyses were replicated by RT-qPCR.
EGFL6, TNMD, CES1, HSPB7, LEP, SPARC, VLDLR, LOXL2 were down-regulated and IGFBP3 was up-regulated with increased weight loss during DI (Table 2). These genes were also associated with percent weight lost during CR (p<0.029), and percent weight change during follow-up (p<0.005). Of the 15 genes with 0.05<q<0.20 in DE analyses, 13 were replicated by RT-qPCR, all were down-regulated with increased weight loss during DI (Table 3). AES, CCND1, CRYAB, FAM198B, FSTL3, INHBB, and LOX were associated with percent weight lost during CR (p<0.012), and all except FSTL3 were associated with percent weight change during follow-up (p<0.010) (Supplementary Table 7). Of these 22 genes, 19 (excluding TNMD, NOMO1, and TPST2) had significant associations with changes in fat mass, showing consistent directional effects with changes in BMI (Supplementary Table 7).

Figure 2b shows trajectories of expression during DI for the 22 validated genes, plotted by groups of decrease in BMI during the DI (Supplementary Table 2 shows clinical characteristics of the groups). IGFBP3 had an inverted profile, being up-regulated during CR, then during follow-up had stabilized (higher) expression in individuals that had the greatest decrease in BMI, and was down-regulated in individuals that regained weight. All other genes were down-regulated during CR. During follow-up LEP, SPARC, HSPB7, CES1, VLDLR, AES, and LOX had stabilized (lower) expression in individuals that had the greatest decrease in BMI, while EGFL6, TNMD, CRYAB, AKR1C3, FSTL3, FAM198B, and MTCH2 had continued down-regulation in individuals that had the greatest decrease in BMI.

Potential secreted biomarkers

To characterize potential circulating biomarkers we measured expression of selected genes in adipocytes and SVF isolated from AT, checked for secretion, and measured secreted factors in plasma from individuals that decreased BMI by >10 or <0, representing the top and bottom 5th percentile of change in BMI (Supplementary Table 2). EGFL6, TNMD, SPARC, FSTL3, and CRYAB were predominantly or exclusively expressed in adipocytes, whereas IGFBP3 was predominantly expressed in the SVF (Figure 2c). Regarding secretion, EGFL6, FSTL3 and CRYAB were detected in media from adipocytes but not SVF, IGFBP3 was detected in both media (Table 4). Figure 2d shows changes in plasma concentrations during DI, there were significant decreases in EGFL6 (57%, p=0.03), FSTL3 (26%, p=0.01) and CRYAB (23%, p=0.07) in the group that decreased BMI by >10, and no significant changes in the group with a change in BMI <0. There were no significant changes in plasma IGFBP3 in either group (p=0.31). We also found a positive correlation between BMI and FSTL3 levels in media from adipocytes (r=0.79, p<0.05; Supplementary Figure 3), and plasma (r=0.52, p<0.05, not shown).

Differential expression independent of the dietary intervention

Discovery analysis using microarray

We identified 209 genes that were differentially expressed at both baseline and at the end of DI, which we considered to have classified poor- and good-controllers independent of DI, with about half more highly...
Validation analyses using RT-qPCR

We selected 17 of the 209 classifier genes for validation by RT-qPCR, based on largest expression ratios at baseline and enriched for genes encoding secreted proteins. Of these, only ASPN and USP53 showed associations with changes in BMI during DI. Higher baseline expression of ASPN was associated with a greater decrease in BMI during DI (p<0.001), as well as higher baseline BMI (p<0.001) and continued weight loss during follow-up (p=0.001). When an interaction with baseline BMI was included, baseline expression of USP53 was found to be associated with changes in BMI during DI (p=0.012, interaction p=0.008), having higher baseline expression in individuals that lost more weight during DI for individuals with higher baseline BMI. This association was attenuated when adjusted for centre, a potential confounder. There was also a positive association between baseline expression of USP53 and baseline BMI (p=0.002). Figure 3a shows trajectories of expression during DI for ASPN and USP53, for which baseline expression appears to be associated with weight control after CR.

Properties of the validated classifiers

ASPN was predominantly expressed in the SVF, whereas USP53 was expressed in both adipocytes and SVF (Figure 3b). Evaluation of secretion of ASPN in AT fractions and plasma failed, as most samples were below the detection limit (8.59 pg/ml).

eQTL analysis

There was a genome-wide significant cis-eQTL and an almost significant trans eQTL between SNPs and RT-qPCR expression levels of USP53. The cis-eQTL included SNPs downstream of USP53 (lead SNP: rs2168987; p=3.1E-08; minor allele frequency=0.44), shown in Figure 3c. The minor T allele of rs2168987 has been previously shown to be associated with higher USP53 expression in AT (FDR<5%) (19). The trans-eQTL was on another chromosome, within ZAK (MAP3K MLT; lead SNP: rs3769187; p=2.3E-07; minor allele frequency=0.21).

DISCUSSION

We aimed to identify biomarkers of weight control using individuals from the DiOGenes Study, a 2-phase DI including a 8-week CR phase and a 6-month ad libitum follow-up. To this end, we used AT transcriptomics to identify genes affected by weight change during the DI, as well as genes that were indicative of successful weight control after CR. We validated our results using RT-qPCR on a larger cohort from the same study, and focused on genes encoding secreted proteins. Discovery analysis compared groups of extreme responders: good-controllers (maintained weight loss during follow-up), and poor-controllers (regained weight during follow-up). Our discovery analyses made use of a small sample size, thus we
applied a relaxed selection criteria and assessed the robustness of the identified genes using a larger replication cohort. We did not adjust for energy intake as data was missing for almost half of the individuals used in these analyses. Diverged genes were altered in response to weight changes during DI; among the 22 validated diverged genes we confirmed 3 as potential circulating biomarkers. Two genes for which baseline expression was indicative of weight control after CR were validated, their expression was not altered in response to the DI.

We have previously shown that AT signatures reflect the capacity to maintain body weight after CR (6), and that genes are generally down-regulated during CR (7,11). Here we found an exception, IGFBP3 (Insulin-like growth factor binding protein 3) was up-regulated during CR, and subsequently down-regulated with weight gain during follow-up. At the end of DI individuals that decreased BMI by >10 had 56% higher AT expression of IGFBP3 than those that returned to baseline weight. IGFBP3 encodes the main insulin-like growth factor transport protein in blood and is known to inhibit adipogenesis (20) and to repress the transforming growth factor β1 (TGFβ1, a secreted cytokine in the TGFβ superfamily) signaling pathway (21). Pathway analysis found a regulatory network controlled by TGFBI, although TGFBI was not identified as differentially expressed in these analyses. We found that genes identified as diverged during DI were predominantly expressed in adipocytes rather than the SVF. Amongst the best candidate genes was TNMD, encoding tenomodulin, a type II transmembrane glycoprotein, whose expression was down-regulated in response to weight loss, and has been positively correlated with BMI (22). TNMD is known to be required for adipocyte differentiation and has been suggested as a protective factor against insulin resistance by promoting hyperplasia and beneficial lipid storage in visceral AT (23). We focused further work on other top candidates (EGFL6, FSTL3 and CRYAB) encoding secreted proteins and with little known in the context of weight control.

To evaluate whether these could serve as circulating biomarkers, we compared plasma protein levels from individuals that decreased BMI >10 points and those that returned to baseline BMI at the end of DI. We found significant intra-individual decreases in circulating EGFL6, FSTL3 and CRYAB during DI in individuals with good weight control, but no change in individuals with poor weight control. This was consistent with changes in AT expression of EGFL6, FSTL3 and CRYAB and suggests that secretion from AT likely contributes to plasma levels of these proteins. EGFL6 encodes epidermal growth factor-like domain multiple-6, a member of the epidermal growth factor repeat superfamily. It has been suggested that this paracrine/autocrine growth factor of AT is an extracellular matrix protein (24). EGFL6 has previously been shown to have higher AT expression and secretion in obese versus lean individuals, to be down-regulated in obese patients after surgery-induced weight loss, and is potentially involved in the process of AT expansion and the development of obesity (24,25). Here, we showed long-term down-regulation of EGFL6 after CR induced weight loss. CRYAB, encoding an α-crystallin B chain, has been previously shown to have a positive association between BMI and AT expression, and increased levels during adipogenesis (26). While EGFL6 and CRYAB are known adipokines, this is the first report of FSTL3 as an adipokine. FSTL3, encodes follistatin-like 3, a member of the follistatin (FST)-related protein family (27). FST is known as an adipokine.
with reduced expression and secretion in obese versus lean women (28). Both FST and FSTL3 are antagonists of activin and myostatin (29). FSTL3 is released by muscles (30) and adipose tissue (27). Here, we found a positive relationship between changes in BMI and FSTL3 expression in AT, secretion by human adipocytes, and FSTL3 in plasma. Studies on FSTL3 null mice have shown a differential role of FST and FSTL3 on glucose homeostasis and body composition (31). Our observation of decreased FSTL3 expression and plasma FSTL3 levels with greater decreases in BMI reveals a discrepancy between FST and FSTL3 regarding body weight control.

A remarkable outcome of this study was the identification of genes for which baseline expression was associated with changes in BMI during DI. ASPN and USP53 had higher baseline expression in individuals that exhibited better weight control after CR. ASPN (Asporin) had 2-fold higher baseline expression in individuals that went on to decrease BMI by >10 points versus those that returned to baseline weight during follow-up. High ASPN expression in AT appears to be a hallmark of individuals that successfully maintained weight loss, as ASPN expression was not regulated during CR or follow-up. We also found that ASPN was predominantly expressed in the SVF of AT, rather than adipocytes. ASPN belongs to a family of leucine-rich repeat proteins associated with the extracellular matrix and has been found to be expressed in many tissues (32). It has been suggested that extracellular matrix may constrain AT expandability (33), and here higher expression of ASPN in AT was relevant for the prevention of weight (re)gain. ASPN is a tumor suppressor and a TGFβ1 inhibitor (34). This corresponds with our gene expression data showing higher baseline expression of ASPN associated with a greater decrease in BMI; suggesting that increased inhibition of the TGFβ1 pathway by ASPN resulted in increased weight control after CR. USP53 encodes ubiquitin specific peptidase 53, a tight junction-associated protein (35). The association between weight control and USP53 was dependent on baseline BMI; here we found that in more obese individuals, higher expression was associated with increased weight loss. USP53 expression was found to be genetically controlled as well, with both cis- and trans-eQTL. Our results indicate that AT mRNA levels of ASPN and USP53 might be of interest as prognostic indicators of long-term response to weight reducing diets.

An interesting observation is the implication of TGFβ1, a multifunctional growth factor with pro-fibrotic properties (32), both as a regulator of expression of certain genes that were down-regulated during DI, and as a target for ASPN that had higher expression during DI, in individuals with good weight control after CR. It has been suggested that excess fibrosis in AT may alter tissue remodeling and restrain loss of fat mass (36). The consistency of these observations emphasizes the potential role of AT fibrosis in long-term weight control.

In the present study, we identified a novel adipokine (FSTL3), as well as circulating biomarkers of weight control after CR that are secreted from adipocytes (EGFL6, CRYAB, and FSTL3). We also identified genes for which higher expression was associated with increased weight control after weight loss (ASPN and USP53). For use as biomarkers, these genes and circulating factors now need to be evaluated in other cohorts.


Oberauer R, Rist W, Lenter MC, Hamilton BS, Neubauer H. EGFL6 is increasingly expressed in human obesity and promotes proliferation of adipose tissue-derived stromal vascular cells. Molecular and cellular biochemistry 2010; 343:257-269


Allen DL, Cleary AS, Speaker KJ, Lindsay SF, Uyenishi J, Reed JM, Madden MC, Mehan RS. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. American journal of physiology Endocrinology and metabolism 2008; 294:E918-927


Henningsen J, Rigbolt KT, Blagoev B, Pedersen BK, Kratchmarova I. Dynamics of the
skeletal muscle secretome during myoblast differentiation. Molecular & cellular proteomics

Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis.

32. Luo T, Nocon A, Fry J, Sherban A, Rui X, Jiang B, Xu XJ, Han J, Yan Y, Yang Q, Li Q,
Zang M. AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix
Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity. Diabetes
2016; 65:2295-2310

adipocyte: a model for integration of cytokine signaling in the regulation of energy
metabolism. American journal of physiology Endocrinology and metabolism 2015;
309:E691-714

34. Maris P, Blomme A, Palacios AP, Costanza B, Bellahcene A, Bianchi E, Gofflot S, Drion P,
Trombino GE, Di Valentin E, Cusumano PG, Maweja S, Jerusalem G, Delvenne P, Lifrange
E, Castronovo V, Turtoi A. Asporin Is a Fibroblast-Derived TGF-beta1 Inhibitor and a
Tumor Suppressor Associated with Good Prognosis in Breast Cancer. PLoS medicine 2015;
12:e1001871

Schwander M. Progressive Hearing Loss in Mice Carrying a Mutation in Usp53. The
Journal of neuroscience : the official journal of the Society for Neuroscience 2015;
35:15582-15598

M, Poitou C, Zucker JD, Bedossa P, Clement K. Fibrosis in human adipose tissue:
composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes 2010;
59:2817-2825
Table 1. Clinical characteristics of study participants with good- or poor-weight control during DI.

<table>
<thead>
<tr>
<th></th>
<th>Good-controllers (n=11)</th>
<th>Poor-controllers (n=10)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex (M/F)</strong></td>
<td>4 / 7</td>
<td>2 / 8</td>
<td></td>
</tr>
<tr>
<td><strong>Diet (n)</strong></td>
<td>1(3), 2(1), 3(2), 5(5)</td>
<td>1(0), 2(4), 3(1), 5(5)</td>
<td></td>
</tr>
<tr>
<td><strong>Age (yr)</strong></td>
<td>11</td>
<td>10</td>
<td>0.777</td>
</tr>
<tr>
<td><strong>Percentage Weight Lost (%)</strong></td>
<td>11</td>
<td>10</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>LCD Weight Lost (kg)</strong></td>
<td>11</td>
<td>10</td>
<td>0.002</td>
</tr>
<tr>
<td><strong>Percent LCD Weight Lost (%)</strong></td>
<td>11</td>
<td>10</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>BMI (kg/m2)</strong></td>
<td>11</td>
<td>10</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Total Energy (kJ/day)</strong></td>
<td>11</td>
<td>9</td>
<td>0.062</td>
</tr>
<tr>
<td><strong>Fat Mass (%)</strong></td>
<td>9</td>
<td>10</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Waist Circumference (cm)</strong></td>
<td>10</td>
<td>10</td>
<td>0.028</td>
</tr>
<tr>
<td><strong>Waist to Hip Ratio</strong></td>
<td>10</td>
<td>10</td>
<td>0.648</td>
</tr>
<tr>
<td><strong>SBP (mmHg)</strong></td>
<td>9</td>
<td>10</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>DBP (mmHg)</strong></td>
<td>9</td>
<td>10</td>
<td>0.072</td>
</tr>
<tr>
<td><strong>Fasting Cholesterol (mmol/L)</strong></td>
<td>11</td>
<td>10</td>
<td>0.058</td>
</tr>
<tr>
<td><strong>Fasting HDL (mmol/L)</strong></td>
<td>11</td>
<td>10</td>
<td>0.563</td>
</tr>
<tr>
<td><strong>Fasting LDL (mmol/L)</strong></td>
<td>11</td>
<td>10</td>
<td>0.031</td>
</tr>
<tr>
<td><strong>Fasting TG (mmol/L)</strong></td>
<td>11</td>
<td>10</td>
<td>0.058</td>
</tr>
<tr>
<td><strong>Fasting Fructosamine (µmol/L)</strong></td>
<td>11</td>
<td>10</td>
<td>0.802</td>
</tr>
<tr>
<td><strong>Fasting Adiponectin (µg/mL)</strong></td>
<td>11</td>
<td>10</td>
<td>0.292</td>
</tr>
<tr>
<td><strong>Fasting CRP (mg/L)</strong></td>
<td>10</td>
<td>9</td>
<td>0.015</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>4.99 (0.64)</td>
<td>11</td>
</tr>
<tr>
<td>------------------------</td>
<td>------</td>
<td>------------</td>
<td>----</td>
</tr>
<tr>
<td><strong>Fasting Glucose (mmol/L)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fasting Insulin (µIU/mL)</strong></td>
<td>11</td>
<td>8.11 (4.37)</td>
<td>7</td>
</tr>
<tr>
<td><strong>HOMA-IR</strong></td>
<td>10</td>
<td>1.96 (1.07)</td>
<td>7</td>
</tr>
</tbody>
</table>

* P from Mann-Whitney U test  ** P from bootstrapped mixed robust ANOVA (interaction term) testing whether the intra-individual changes in measures between baseline and after the dietary intervention were different between the groups (Mann-Whitney U test comparing the groups at baseline and end of follow-up are available in Supplementary Table 1).

Data are presented as (mean + sd). Groups represent good- and poor- controllers used in microarray analyses.

DI – dietary intervention; BMI – Body mass index; SBP – Systolic blood pressure; DBP – Diastolic blood pressure; HDL – High density lipoprotein; LDL – low density lipoprotein; TG – triglycerides; CRP – C-reactive protein; HOMA-IR – homeostatic model assessment index for insulin resistance
### Table 2.
Differential expression and validation results for 27 genes (q<0.05) with diverged expression associated with changes in BMI during the dietary intervention

<table>
<thead>
<tr>
<th>Genes more highly expressed in poor-controllers</th>
<th>Discovery analyses (n=21)</th>
<th>Validation analyses (n=310)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ratio after DI *</td>
<td>q-value</td>
</tr>
<tr>
<td>EGFL6 s</td>
<td>2.70</td>
<td>0.037</td>
</tr>
<tr>
<td>TNMD</td>
<td>1.41</td>
<td>0.042</td>
</tr>
<tr>
<td>CES1</td>
<td>1.31</td>
<td>0.003</td>
</tr>
<tr>
<td>UCHL1</td>
<td>1.26</td>
<td>0.035</td>
</tr>
<tr>
<td>HSPB7</td>
<td>1.16</td>
<td>0.011</td>
</tr>
<tr>
<td>LEP s</td>
<td>1.16</td>
<td>0.014</td>
</tr>
<tr>
<td>TNFRSF25</td>
<td>1.03</td>
<td>0.031</td>
</tr>
<tr>
<td>SPARC s</td>
<td>0.96</td>
<td>0.042</td>
</tr>
<tr>
<td>ABCC6</td>
<td>0.90</td>
<td>0.015</td>
</tr>
<tr>
<td>NANGS1</td>
<td>0.90</td>
<td>0.044</td>
</tr>
<tr>
<td>VLDLR</td>
<td>0.88</td>
<td>0.042</td>
</tr>
<tr>
<td>SYNO</td>
<td>0.87</td>
<td>0.050</td>
</tr>
<tr>
<td>LOXL2 s</td>
<td>0.86</td>
<td>0.006</td>
</tr>
<tr>
<td>ASAH1</td>
<td>0.82</td>
<td>0.006</td>
</tr>
<tr>
<td>MRAS</td>
<td>0.76</td>
<td>0.015</td>
</tr>
<tr>
<td>VKORC1L1</td>
<td>0.74</td>
<td>0.026</td>
</tr>
<tr>
<td>GLIPR2</td>
<td>0.73</td>
<td>0.050</td>
</tr>
<tr>
<td>GPX1</td>
<td>0.72</td>
<td>0.042</td>
</tr>
<tr>
<td>MTO1</td>
<td>0.70</td>
<td>0.026</td>
</tr>
<tr>
<td>CALU</td>
<td>0.64</td>
<td>0.045</td>
</tr>
<tr>
<td>HTRA1 s</td>
<td>0.63</td>
<td>0.024</td>
</tr>
<tr>
<td>LOC729013</td>
<td>0.53</td>
<td>0.031</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genes more highly expressed in good-controllers</th>
<th>Discovery analyses (n=21)</th>
<th>Validation analyses (n=310)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ratio after DI *</td>
<td>q-value</td>
</tr>
<tr>
<td>EIF4B</td>
<td>-0.47</td>
<td>0.044</td>
</tr>
<tr>
<td>BTF3P11</td>
<td>-0.56</td>
<td>0.035</td>
</tr>
<tr>
<td>AASS</td>
<td>-0.56</td>
<td>0.035</td>
</tr>
<tr>
<td>ADH1B</td>
<td>-0.85</td>
<td>0.015</td>
</tr>
<tr>
<td>IGFBP3 s</td>
<td>-0.89</td>
<td>0.003</td>
</tr>
</tbody>
</table>

s genes that encode secreted proteins.

* ratio of expression at end of dietary intervention = poor-controllers/good-controllers
‡ positive log2FC means expression increased during dietary intervention (DI)
§ estimate for age and sex adjusted association between change in expression and change in BMI during dietary intervention (change calculated as end of DI - baseline)
Differential expression and validation results for 13 genes (0.05<q<0.20) with validated diverged expression associated with changes in BMI during the dietary intervention

<table>
<thead>
<tr>
<th></th>
<th>Discovery analyses (n=21)</th>
<th>Validation analyses (n=310)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ratio after DI * q-value</td>
<td>mean log2FC ‡ estimate § p-value</td>
</tr>
<tr>
<td><strong>AKR1C3</strong></td>
<td>0.97</td>
<td>0.16 / -0.80</td>
</tr>
<tr>
<td><strong>VGLL3</strong></td>
<td>0.86</td>
<td>0.22 / -0.64</td>
</tr>
<tr>
<td><strong>FSTL3</strong></td>
<td>0.85</td>
<td>0.26 / -0.59</td>
</tr>
<tr>
<td><strong>MTCH2</strong></td>
<td>0.81</td>
<td>0.28 / -0.52</td>
</tr>
<tr>
<td><strong>FAM198B</strong></td>
<td>0.72</td>
<td>0.28 / -0.44</td>
</tr>
<tr>
<td><strong>LOX</strong></td>
<td>0.69</td>
<td>0.29 / -0.40</td>
</tr>
<tr>
<td><strong>CRYAB</strong></td>
<td>0.63</td>
<td>0.14 / -0.49</td>
</tr>
<tr>
<td><strong>CCND1</strong></td>
<td>0.62</td>
<td>0.19 / -0.43</td>
</tr>
<tr>
<td><strong>MECR</strong></td>
<td>0.57</td>
<td>0.20 / -0.38</td>
</tr>
<tr>
<td><strong>TPST2</strong></td>
<td>0.52</td>
<td>0.08 / -0.45</td>
</tr>
<tr>
<td><strong>NOMO1</strong></td>
<td>0.44</td>
<td>0.14 / -0.30</td>
</tr>
<tr>
<td><strong>INHBB</strong></td>
<td>0.43</td>
<td>0.25 / -0.19</td>
</tr>
<tr>
<td><strong>AES</strong></td>
<td>0.36</td>
<td>0.18 / -0.18</td>
</tr>
</tbody>
</table>

* genes that encode secreted proteins.
* ratio of expression at end = poor-controllers/good-controllers
‡ positive log2FC means expression increased during dietary intervention (DI)
§ estimate for age and sex adjusted association between change in expression and change in BMI during dietary intervention (change calculated as end of DI - baseline)
Table 4. Localization of secretion of protein in adipose tissue fractions

<table>
<thead>
<tr>
<th>Adipokine</th>
<th>Adipocytes (pg/ml)</th>
<th>SVF (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFL6</td>
<td>26.8 ± 1.9</td>
<td>&lt;19.5</td>
</tr>
<tr>
<td>FSTL3</td>
<td>25.9 ± 1.9</td>
<td>&lt;10</td>
</tr>
<tr>
<td>CRYAB</td>
<td>107.3 ± 31.0</td>
<td>&lt;3.2</td>
</tr>
<tr>
<td>IGFBP3</td>
<td>1432 ± 357</td>
<td>451 ± 335</td>
</tr>
</tbody>
</table>

Adipokines concentration was measured in media from isolated adipocytes and stroma-vascular cells (SVF) from human subcutaneous abdominal adipose tissue cultured for 24h (n=7). Data are presented as mean ± sem.
Figure 1. Flowcharts of DiOGenes study design and analyses results.

DiOGenes Dietary Intervention

Assessed for eligibility (n=1209)

Excluded n=271 - did not meet inclusion criteria

Included at baseline & followed low-calorie diet for 8 weeks (n=938)

Excluded n=163 - 8 did not lose >8%
- 157 withdrew

Randomized to ad libitum diets for 6 months (n=773)

Excluded n=225 - withdrew

Completed dietary intervention (n=548; 186 males, 362 females)

231 Individuals available to select extreme responders

21 individuals used in differential expression analyses
(6 men, 15 women)

301 individuals used in validation analyses
(107 men, 203 women)

a. Flowchart of the DiOGenes study population used in differential expression (1) and validation (2) analyses

Path 1: Selection of individuals to include in differential expression (transcriptome) analyses of extreme responders.

Path 2: Selection of individuals for use in validation (RT-qPCR) analyses.

RT-qPCR = Reverse transcription quantitative polymerase chain reaction
b. Flowchart of number of genes identified based on level of significance applied for each: diverged expression during dietary intervention, and differential expression independent of dietary intervention.

Genes that showed diverged expression or were independent of dietary intervention required the stated level of significance at both time-points.

DI = dietary intervention
IPA = Ingenuity pathway analyses
Figure 2. Evaluation of genes identified as having altered expression during the dietary intervention.

a. Heatmap of expression ratios and fold-changes for the 27 genes identified as significantly diverged (q<0.05) during the dietary intervention.

Summary of the top results obtained from differential expression analyses of microarray expression data (n=21). The two columns on the left represent log$_2$ ratios of expression (poor-controllers / good-controllers) at baseline and after DI. The two columns on the right represent log$_2$ FC during the dietary intervention for good-controllers and poor-controllers. Legend shows log$_2$ values.

log$_2$ FC = log$_2$ Fold-change.
b. Evolution of expression for 22 genes validated by RT-qPCR.

Evolution of relative expression measured by RT-qPCR (n=310) at baseline, end of calorie-restriction (CR), and end of the dietary intervention (DI), grouped by decrease in BMI during the DI, and ordered by patterns of changes in expression. Points represent mean relative expression for each group and bars represent mean +/- sem.
c. Localization of expression in adipose tissue for 6 genes encoding secreted proteins.

Expression levels of EGFL6, TNMD, SPARC, FSTL3, CRYAB, and IGFBP3 in adipose tissue, adipocytes, and stroma-vascular fraction. mRNA levels were measured in paired samples of freshly isolated adipocytes (n=7) and stroma-vascular fraction (SVF, n=6) from human subcutaneous abdominal adipose tissue (n=5). Data are presented as mean ± sem.
d. Changes in plasma levels for 4 genes encoding secreted proteins.

Intra-individual changes in plasma levels of EGFL6, CRYAB, FSTL3 and IGFBP3. Protein levels were measures in plasma samples obtained before and at the end of dietary intervention, for individuals from the top 5 percentiles of changes in BMI during the dietary intervention (poor weight control, n = 7-9; good weight control, n = 8-9).
Figure 3. Evaluation of genes identified as classifiers of weight control independent of the dietary intervention.

a. Evolution of expression for ASPN and USP53 identified as classifiers at validated by RT-qPCR.
Evolution of relative expression measured by RT-qPCR (n=310) at baseline, end of calorie-restriction (CR), and end of the dietary intervention (DI), grouped by decrease in BMI during the DI. Points represent mean relative expression for each group and bars represent mean +/- sem.

b. Localization of expression in adipose tissue cells for ASPN and USP53.
Expression levels of ASPN and USP53 in adipose tissue, adipocytes, and stroma-vascular fraction (SVF). mRNA level was determined in paired samples of freshly isolated adipocytes (n=7) and SVF (n=6) from human subcutaneous abdominal adipose tissue (n=5). Data are presented as mean ± sem.
c. LocusZoom plot of rs2168987 identified by eQTL analyses to be associated with expression of USP53

Plot showing the lead SNP identified by eQTL analysis as a purple diamond. The y-axis represents -log10 p-values obtained from eQTL analyses, and the points are coloured to represent correlation with the lead SNP. Points in red are interchangeable with the lead SNP, whereas points in blue are independent.